Scientists are researching resistant bacteria to improve and revive use of existing last-line anti-infective treatments
Xellia Pharmaceuticals is opening a new active pharmaceutical ingredients (API) R&D Centre of Excellence in Oslo, Norway. Xellia specialises in the manufacture of quality, fermented and difficult-to-manufacture APIs and is also developing APIs based on chemical synthesis, which involves complex, strictly controlled chemical reactions, using its innovative Route-of-Synthesis procedures.
The new 1,900m2 facility replaces the R&D centre at the former manufacturing site in Oslo. Xellia’s 50 specialist API researchers are focusing on developing new APIs and on the identification of improvements in microbial strain development as well as fermentation and purification processes to increase the yield and efficiencies in the upstream and downstream manufacturing process.
The research team is also working in partnership with scientists at SINTEF Materials and Chemistry (Trondheim, Norway) and the Statens Serum Institute (Copenhagen, Denmark). The scientists are researching resistant bacteria to improve and revive use of existing last-line anti-infective treatments. In addition, Xellia is working with these partners to discover new lead compounds that will target multi-drug resistant Gram-negative bacteria.